ArticleJournal of natural medicines2026
Digoxin targets BHLHE40 to inhibit epithelial-mesenchymal transition in cervical cancer cells via downregulation of ANGPTL3.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting NUDT21-mediated alternative polyadenylation of oncogenes ameliorates colorectal cancer malignancy and metastasis.British journal of cancer · 2026Article
- Revisiting the Lipid-Cancer Axis: PCSK9, ANGPTL3, and CETP as Emerging Biomarkers and Therapeutic Targets in Oncology.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aims to investigate the mechanism of action of BHLHE40 and its targeted drug, digoxin, in cervical cancer. The clinical significance of BHLHE40 was evaluated in cervical cancer samples using the UALCAN and Human Protein Atlas databases. The effects of BHLHE40 on proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) were then assessed through loss- and gain-of-function experiments coupled with CCK-8, wound healing, Transwell and Western blot analysis. A murine lung-metastasis model was further established to `validate the pro-metastatic role of BHLHE40 in vivo. JASPAR-based motif prediction, chromatin immunoprecipitation-qPCR (ChIP-qPCR), and luciferase reporter assays were employed to elucidate the transcriptional regulation of ANGPTL3 by BHLHE40. Molecular docking and cellular thermal shift assay (CETSA) were used to clarify the molecular interaction between digoxin and BHLHE40. BHLHE40 was markedly up-regulated in cervical cancer tissues and positively correlated with advanced tumor stage, lymph node metastasis, and poor prognosis. Knockdown of BHLHE40 suppressed proliferation, colony formation, migration, invasion, and attenuated EMT. Consistently, silencing BHLHE40 reduced the number of pulmonary metastatic nodules in nude mice. Mechanistically, BHLHE40 bound directly to the ANGPTL3 promoter and enhanced its transcriptional activity. Knock-down ANGPTL3 reversed BHLHE40-induced increases in migratory and invasive capacities as well as EMT-related phenotypic changes. Digoxin bound to the conserved domain of BHLHE40, down-regulated both BHLHE40 and ANGPTL3, and suppressed EMT and cell motility. Overexpression of BHLHE40 rescued these inhibitory effects of digoxin. Collectively, our findings demonstrate that BHLHE40 promotes EMT and metastasis in cervical cancer by transcriptionally activating ANGPTL3, whereas digoxin exerts anti-EMT effects by targeting this axis. These data highlight the critical role of the BHLHE40-ANGPTL3 axis in cervical cancer progression and suggest that repurposing digoxin offers a novel therapeutic strategy for suppressing EMT in this disease.
Indexed as
Identifiers
41193709What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.